Please assess the completion status of the following clinical trial:

Trial Title: A Real-world Study of Imraldi® Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Initiation on Imraldi® therapy after 18th October 2018, as part of routine treatment immediately after transitioning from at least 16 weeks' treatment with originator adalimumab (Humira®)~* Availability of at least one Baseline disease score (i.e. within 16 weeks prior or up to 6 weeks post-initiation of Imraldi®)~* Should provide informed consent to participate in the study~Exclusion Criteria:~- Unlikely to attend for regular clinic visits for the duration of study follow-up, in the opinion of the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab Therapy (Type: None): Adult participants diagnosed with immune-mediated inflammatory disease will receive adalimumab as a prescribed therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).